Pharsight

Bridion patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44733 ORGANON SUB MERCK 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Jan, 2026

(1 year, 9 months from now)

Bridion is owned by Organon Sub Merck.

Bridion contains Sugammadex Sodium.

Bridion has a total of 1 drug patent out of which 0 drug patents have expired.

Bridion was authorised for market use on 15 December, 2015.

Bridion is available in solution;intravenous dosage forms.

Bridion can be used as reversal of drug-induced neuromuscular block.

The generics of Bridion are possible to be released after 27 January, 2026.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jun 25, 2024
M (M) Jan 22, 2024

Drugs and Companies using SUGAMMADEX SODIUM ingredient

Market Authorisation Date: 15 December, 2015

Treatment: Reversal of drug-induced neuromuscular block

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of BRIDION before it's drug patent expiration?
More Information on Dosage

BRIDION family patents

Family Patents